A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Study Summary

A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])

Conditions

Cushing Syndrome Cushing Disease Ectopic ACTH Syndrome

Interventions / Drugs

atumelnant

View on ClinicalTrials.gov ↗

Sponsor

CRNX

Crinetics Pharmaceuticals

Endocrinology

D39/100

Study Details

Enrollment18 participants

Primary Completion—

Lead SponsorCrinetics Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:10:51.260423+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.